Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Addressing catheter lock therapy: Does heparin reduce the bioactivity of dalbavancin when together in solution during freezing?

Citation

Díaz-Navarro, M., Hafian, R., Pérez-Granda, M. J., Cercenado, E., Muñoz, P., & Guembe, M. (2024). Addressing catheter lock therapy: Does heparin reduce the bioactivity of dalbavancin when together in solution during freezing? Enfermedades Infecciosas y Microbiologia Clinica (English Ed.), 42(8), 435-438. https://doi.org/10.1016/j.eimce.2024.02.013

Abstract

Introduction: The possible use of dalbavancin as a catheter lock solution was previously demonstrated by our study group. However, it was needed to assess whether heparin could affect dalbavancin bioactivity during freezing storage. Methods: We tested the bioactivity of a dalbavancin+heparin (DH) vs. dalbavancin (D) against Staphylococcal biofilms comparing DH median value of cfu counts and metabolic activity with that obtained for D before and during storage under freezing up to 6 months. Results: Despite there was a slight decrease in the median percentage reduction of metabolic activity at month 3 in Staphylococcus epidermidis between DH and D (97.6 vs. 100, p=0.037), considering the clinical criteria, no significant reduction in any of the variables tested was observed at the end of the experiment between D and DH solutions. Conclusion: The addition of heparin to a dalbavancin lock solution did not affect its bioactivity against staphylococcal biofilms irrespective of its preservation time under freezing. Keywords: Bioactividad; Bioactivity; Biofilms; Biopelículas; Congelación; Dalbavancin; Dalbavancina; Freezing; Heparin; Heparina; Lock therapy; Terapia de sellado.

Research Projects

Organizational Units

Journal Issue

Description

M. Guembe is supported by the Miguel Servet Program (ISCIII-MICINN, MS18/00008) of the Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid, Spain. M. Díaz-Navarro is supported by ISCIII (FI22/00022). The study was partially financed by grants from the ISCIII (PI21/00344), the Fundación Mutua Madrileña (FMM21/01), IiSGM (2022-PI-II-COOPTR-01), and the European Regional Development Fund (FEDER) “A way of making Europe”.

Keywords

Collections